IDNA - iShares prepares to launch a Neuroscience and Healthcare ETF

Blackrock outlined its plan to launch the iShares Neuroscience and Healthcare ETF in a U.S. Securities Exchange Commission filing that was put together on Wednesday. The new iShares fund will offer the investment community access to equity securities that are involved in the research, development or manufacturing of neurology biopharmaceuticals or neurological devices. The ETF will also be classified within one of two sub-industries: neurology biopharmaceuticals and neurology devices.  The niche healthcare fund looks to launch at a time when the overall healthcare sector (NYSEARCA:XLV) is -3.9% year-to-date. Furthermore, the ETF will also pair well with its brother and sister ETFs, the iShares Biotechnology ETF (IBB) and the iShares Genomics Immunology and Healthcare ETF (IDNA). Moreover, according to the prospectus, the exchange traded fund intends to track the NYSE FactSet Global Neuro Biopharma and MedTech Index. Additionally, per the filing, no expense ratio or ticker symbol was listed at this time. Year-to-date

For further details see:

iShares prepares to launch a Neuroscience and Healthcare ETF